Investigators found in hepatocytes that USP13 inhibits lipid accumulation-associated steatohepatitis and inflammation-triggered NASH by directly binding to inactive rhomboid protein 2 (IRHOM2) and modifying IRHOM2 with K63-type deubiquitination, thereby reducing IRHOM2 stability and abundance (37). Here, USP13 is linked to metabolic dysfunction-associated steatohepatitis.